Table 2:

Factors associated with digoxin use

	OR	95% CI	p
Discharge ≥1/1/2016	2.52	2.22–2.85	<0.001
Male sex	1.18	1.05–1.32	0.005
Race
Non-Hispanic white	1	n/a	n/a
Hispanic white	0.84	0.70–1.00	0.06
Non-Hispanic black	1.08	0.90–1.29	0.40
Other Hispanic	0.80	0.64–1.02	0.07
Other or more than one race	1.41	1.04–1.93	0.03
Missing	0.68	0.57–0.82	<0.001
Payer
Commercial	1	n/a	n/a
Medicaid	0.95	0.85–1.07	0.44
Other government	0.72	0.54–0.98	0.04
Other	0.54	0.40–0.72	<0.001
Missing	0.40	0.20–0.79	0.008
Prematurity (<37 weeks GA)	0.69	0.56–0.85	<0.001
Genetic syndrome	0.54	0.37–0.77	0.001
Neurological condition	0.79	0.61–1.01	0.06
Respiratory condition	0.95	0,77–1.18	0.67
Renal condition	0.69	0.58–0.82	<0.001
Gastrointestinal condition	1.23	1.08–1.40	0.002
Hematological condition	0.99	0.68–1.45	0.97
Metabolic disorder	0.96	0.74–1.26	0.79
Technology dependent	1.16	1.03–1.32	0.01
Arrhythmia	1.57	1.38–1.78	<0.001
ECMO during hospitalization	1.49	1.23–1.80	<0.001
Cardiac arrest during hospitalization	0.78	0.53–1.15	0.20
Total LOS > median (32 days)	1.55	1.38–1.73	<0.001
Aspirin	2.64	2.33–3.00	<0.001
Furosemide	3.42	2.93–4.00	<0.001
Opiate	0.66	0.43–0.99	0.04

Abbreviations: ECMO extracorporeal membrane oxygenation, GA gestational age, LOS length of stay